• Purity

  >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

• Endotoxin Level

  <1.0 EU per 1 μg of the protein by the LAL method.  

• Activity

  Measured by the ability of the immobilized protein to support the adhesion of SVEC4‑10 mouse vascular endothelial cells. When 5 x 10    ⁴ cells/well are added to Recombinant Human EDIL3 coated plates (5 µg/mL, 100 µL/well), >45% will adhere after 60 minutes at 37 °C.    
     Optimal dilutions should be determined by each laboratory for each application.  

• Source

  Chinese Hamster Ovary cell line, CHO-derived Val17-Glu480 with a C-terminal 6x His

• Accession #

• N-terminal Sequence    
  Analysis

  Val17, Asp24

• Predicted Molecular Mass

  52 kDa

• SDS-PAGE

  60-65 kDa, reducing conditions

Background: EDIL3

EGF‑like repeat and discoidin I‑like domain‑containing protein 3 (EDIL3; also Del‑1 and integrin‑binding DEL1) is a 52 kDa extracellular matrix protein that is expressed by endothelial tissues during embryonic vascular development (1). Human EDIL3 is synthesized as a precursor with a 16 amino acid (aa) signal sequence and a 464 aa mature chain (SwissProt # O43854). The mature chain is composed of three epidermal growth factor (EGF) repeats and two discoidin‑I‑like domains (1). The second EGF repeat contains an RGD motif (1). Splicing variants produce two isoforms for human EDIL3. Isoform 2 has an A‑>G substitution at aa 66 and a deletion of  
aa 67‑76 found in isoform 1. Mature human EDIL3 shares 96% aa sequence identity with mature mouse EDIL3. The RGD motif of EDIL3 binds alpha v beta 5 integrin, which, in turn, leads to increased angiogenic transcription factor HoxD3 expression (2). HoxD3activates alpha v beta 3 and uPA, resulting in the transformation of resting endothelial cells to an angiogenic state (2‑4). EDIL3 becomes quiescent at the time of birth, and is no longer expressed in normal adult tissues. It has been found, however,  
re‑expressed in a number of human tumors as well as in ischemic muscles and ischemic brain tissue, which may play an important role in adult angiogenesis (2, 5‑6). EDIL3 promotes adherence and migration of endothelial cells, and acts as an endothelial cell survival agent through up‑regulation of Bcl‑2 expression (7). Exogenous application of EDIL3 has been demonstrated to augment angiogenesis and improve blood flow and tissue function in murine models of hind‑limb ischemia (6, 8), cardiac ischemia (9) and cerebral ischemia (2). EDIL3 has also been shown to be an endogenous inhibitor of inflammatory cell recruitment by interfering with the integrin LFA‑1‑dependent leukocyte‑endothelial adhesion (10).

• References:

1. Hidai, C. et al. (1998) Genes Dev. 12:21.

2. Fan, Y. et al. (2008) Brain Res. 1219:1.

3. Penta, K. et al. (1999) J. Biol. Chem. 274:11101.

4. Rezaee, M. et al. (2002) Am. J. Physiol. Heart Circ. Physiol. 282:H1924.

5. Aoka, Y. et al. (2002) Microvasc. Res. 64:148.

6. Ho, H.K. et al. (2004) Circulation 109:1314.

7. Pollman, M.J. et al. (1999) J. Cell Physiol. 178:359.

8. Zhong, J. et al. (2003) J. Clin. Invest. 112:30.

9. Kown, M.H. et al. (2003) Ann. Thorac. Surg. 76:1246.

10. Choi, E.Y. et al. (2008) Science 322:1101.

• Entrez Gene IDs:

  10085 (Human); 13612 (Mouse)

• Alternate Names:

  DEL1; DEL1developmental endothelial locus-1; Developmentally-regulated endothelial cell locus 1 protein; EDIL3; EGF-like repeat and discoidin I-like domain-containing protein 3; EGF-like repeats and discoidin I-like domains 3; Integrin-binding protein DEL1; MGC26287